New data suggest MS 001 could help preserve muscle, reduce weight regain and deepen fat loss alongside GLP-1 drugs.
The obesity drug market has spent the last few years chasing the pounds lost. Well, that made sense at first. GLP-1 drugs changed people’s expectations almost overnight, helping them achieve levels of weight loss once thought possible only through bariatric surgery. Investors rushed in, pharma companies scrambled to build the next blockbuster and patients finally had options that worked. However, as the dust settles, a more nuanced conversation is emerging.
What if the future of obesity treatment isn’t about losing more weight? What if it’s about losing the right weight?
That question mirrors the new data presented by MetaShape Pharma at the 2026 Scientific Sessions of the American Diabetes Association (ADA). The Swiss biotech unveiled preclinical findings suggesting its lead candidate, MS 001, may help address some of the most widely discussed shortcomings of GLP-1 therapies: muscle loss, weight-loss plateaus and the dreaded rebound that often follows treatment discontinuation [1].
The data are still early and confined to animal studies, yet they touch on precisely the questions investors, clinicians and longevity researchers are increasingly asking.
The muscle-sparing holy grail
For years, obesity treatment was viewed through a simple lens: lower body weight equals better health. The reality is proving more complicated.
When people lose weight rapidly, they rarely lose fat alone. Muscle often disappears alongside it. While this may not show up on the bathroom scale, it matters enormously for long-term health. Muscle supports mobility, metabolic health, strength, balance and resilience as we age.
In longevity circles, preserving muscle has become almost as important as losing excess fat. This is why MetaShape’s findings are attracting attention. In obese animal models, the combination of MS 001 and semaglutide delivered deeper weight loss than semaglutide alone. More surprisingly, the animals showed increased muscle weight and greater treadmill endurance.
Think of it this way: most weight-loss therapies are like draining a swimming pool without paying much attention to what leaves with the water. Fat goes out, but valuable muscle often goes with it.
MetaShape is proposing something different. The company’s data suggest the body may be selectively targeting fat while protecting (and potentially improving) lean tissue. If future human trials confirm that effect, it could mark a meaningful shift in how obesity drugs are evaluated. The industry’s next benchmark may not be total weight loss but body composition. A therapy that helps patients lose fat while preserving physical capability could ultimately be more valuable than one that simply produces a lower number on the scale.
“We believe MS 001 has the potential to redefine what successful weight loss looks like in the GLP-1 era,” said Randall Riggs, CEO of MetaShape.
Burning more, not just eating less
Another intriguing aspect of the data is how MS 001 appears to work. Current GLP-1 therapies primarily help people consume fewer calories by reducing appetite and slowing digestion. They are remarkably effective, but they rely heavily on eating less. MS 001 may be approaching the problem from the opposite direction.
The company reported that animals receiving the therapy achieved greater weight loss without further reductions in food intake. Instead, the drug appeared to increase energy expenditure and fat metabolism. Imagine two people reaching the same destination. One gets there by cutting fuel consumption; the other gets there by making the engine run more efficiently. MetaShape believes its therapy helps the body burn more energy rather than merely restricting intake.
“What is particularly compelling is that MS 001 appears to enhance GLP-1 efficacy through increased fat burning and energy expenditure rather than reducing food intake,” said Dr Shanta Bantia, CSO and co-founder of MetaShape.
Breaking the rebound loop
If there is one anxiety shared by many GLP-1 users, it is what happens when treatment stops. The concern is not hypothetical. Research has repeatedly shown that weight often returns after discontinuation. For many patients, this creates a frustrating cycle in which years of progress can begin to unravel within months.
This is where MetaShape’s latest findings may be most provocative. According to the company, animals treated with MS 001 experienced less weight regain after GLP-1 therapy was discontinued. The implications extend beyond weight loss itself. The obesity field has become remarkably good at helping people lose weight. It remains far less effective at helping them maintain it.
That has led some observers to wonder whether the next major opportunity is not another weight-loss drug, but a maintenance therapy – a kind of pharmaceutical off-ramp that helps patients transition away from GLP-1s without falling back into old patterns.
MS 001 is far from proving that role. Human studies will ultimately determine whether the effect translates beyond animal models. Still, the concept is timely. A therapy designed specifically to reduce rebound weight gain could address one of the biggest unresolved challenges in obesity medicine.
The NAD+ connection
Beyond obesity, there is another reason longevity researchers may be paying attention. MS 001 is a purine nucleoside phosphorylase (PNP) inhibitor, a mechanism that MetaShape says elevates plasma inosine and cellular NAD+ levels.
NAD+ is one of the most talked-about molecules in aging research. It plays a central role in how cells generate energy and maintain metabolic function. Declining NAD+ levels have been linked to numerous hallmarks of aging, making it a major focus for scientists exploring ways to extend healthspan. That does not mean MS 001 should be viewed as an anti-aging therapy.
The obesity data and the longevity hypothesis are two separate conversations. Still, the overlap is difficult to ignore. If future research confirms broader metabolic benefits linked to NAD+ biology, the therapy’s potential could extend well beyond weight management.
From weight loss to metabolic health
The most interesting thing about MetaShape’s data is what the findings reveal about where the field is heading. The first generation of obesity drugs proved that substantial weight loss was possible. The next generation appears focused on quality rather than quantity: preserving muscle, improving metabolic health, reducing rebound and potentially delivering more durable outcomes.
MetaShape is currently preparing a $10 million Series A financing round to advance MS 001 toward clinical development, with initial efficacy data anticipated in 2029.
For longevity investors, the company represents a broader trend taking shape across the sector. The future of obesity medicine may be defined by who can help them stay stronger, healthier and metabolically resilient for decades afterward.
